Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,439 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of subsequent treatment for unresectable locally-advanced non-small cell lung cancer after relapse of concurrent chemoradiotherapy with durvalumab consolidation therapy: A single-center retrospective study.
Nishibori Y, Kenmotsu H, Ando K, Tonsho A, Matsuda S, Morita M, Sekikawa M, Doshita K, Morikawa N, Miura K, Kodama H, Yabe M, Iida Y, Mamesaya N, Kobayashi H, Ko R, Wakuda K, Ono A, Naito T, Murakami H, Harada H, Takahashi T. Nishibori Y, et al. Among authors: ono a. Cancer Treat Res Commun. 2024 Nov 8;41:100849. doi: 10.1016/j.ctarc.2024.100849. Online ahead of print. Cancer Treat Res Commun. 2024. PMID: 39536390
A phase II study of ME2136 (Asenapine Maleate) plus standard antiemetic therapy for patients, including diabetic patients, receiving cisplatin-based chemotherapy.
Hamauchi S, Yasui H, Yokota T, Tsushima T, Fushiki K, Naito T, Ono A, Kado N, Onozawa Y, Murakami H, Takahashi T, Hirashima Y, Mori K, Yamazaki K. Hamauchi S, et al. Among authors: ono a. Invest New Drugs. 2024 Oct 26. doi: 10.1007/s10637-024-01480-w. Online ahead of print. Invest New Drugs. 2024. PMID: 39460855
Real-world efficacy and safety of durvalumab-tremelimumab as second-line systemic therapy after atezolizumab-bevacizumab in unresectable hepatocellular carcinoma.
Miura R, Ono A, Yano S, Amioka K, Naruto K, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Nakahara T, Murakami E, Kawaoka T, Miki D, Tsuge M, Hayes CN, Oka S. Miura R, et al. Among authors: ono a. Medicine (Baltimore). 2024 Aug 23;103(34):e39289. doi: 10.1097/MD.0000000000039289. Medicine (Baltimore). 2024. PMID: 39288227 Free PMC article.
1,439 results